Brief: Monopar Therapeutics Reports Third Quarter Results
10/11/2022 13:23
Nov 10 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS AND RECENT PROGRAM DEVELOPMENTS
* MONOPAR THERAPEUTICS INC - VALIDIVE(®) PHASE 2B/3 INTERIM
ANALYSIS ON TRACK FOR Q1 2023
* MONOPAR THERAPEUTICS INC - NET LOSS FOR Q3 OF 2022 WAS
$2.4
MILLION OR $0.19 PER SHARE
Source text for Eikon: ID:nGNX4VDKWP
Further company coverage: MNPR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla